Overview

Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

Status:
Completed

Trial end date:
2010-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the efficacy (ie, healing and symptom relief) and safety of Rabeprazole Extended-Release (RAB ER) 50 mg versus Esomeprazole (ESO) 40 mg for the treatment of moderate to severe erosive Gastroesophageal Reflux Disease (eGERD).

Phase:

Phase 3

Details

Lead Sponsor:

Eisai Inc.

Treatments:

Esomeprazole
Rabeprazole